mrs OKEYSHA BROOKS-COLEY

FY 2022 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; ; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE). HR 869/S. 289 RISE Act of 2021 S.962 - A bill to prioritize funding for an expanded and sustained national investment in biomedical research. Issues related to appropriations for consumer assistance programs, under the Labor, Health and Human Services appropriations bill. HR 2786/S. 1314 - Tobacco Tax Equity Act of 2021 Cures 2.0 RFI - DeGette, Upton ARPA-H Principles

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: The Build Back Better Act, HR 5376 & budget reconciliation discussions HR 1550, The Prevent HPV Cancers Act S 464/HR 2163 Safe Step Act S. 699, Women and Lung Cancer Research and Preventive Services Act of 2021 HR 623, Gabriella Miller Kids First Research Act 2.0 The Palliative Care and Hospice Education and Training Act (soon to be introduced) Provider Training in Palliative Care Act, S 2890 Issues related to the proposed HELP workforce proposal. Issues related to the possible introduction of the 21st Century Cures Act version 2.0 Regulations implementing the No Suprises Act OMB RFI on health equity - comments ACA subsidies expansion permanency - next legislative package Advocacy around subpar health plans - next legislative package DICT RFI - Eshoo DICT Ancillary Costs legislation/Menendez, Scott, Smith, Young, Ruiz House/Senate Appropriations Committee FDA DICT report language Reducing Hereditary Cancer Act of 2021 - DWS, Slotkin, Miller-Meeks, and Davis Personal Care Products Safety Act - Feinstein, Collins H.R. 6638 - Reducing COVID-19 Disparities by Investing in Public Health Act of 2021 The VALID Act - DeGette, Bennet, Burr, Buschon DIVERSE Trials Act - H.R.5030/ S.2706

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending), S. 178 (legislative vehicle for the Protect Act), and HR 925, The Heroes Act. Medical expense deduction - lowering the percentage to 7.5%

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act HR 1948, Lymphedema Treatment Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Senate introduction (no bill number just yet); Issues related to Medicaid Non-Emergency Medical Transportation; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement. HR 2477, Beneficiary Enrollment Notification and Eligibility Simplification Act (BENES) Regulatory issues related to Medicaid and value-based payment HR 7663, Protecting Access to Post COVID 19 Telehealth Act of 2020 The Access to Genetic Counselor Services Act of 2019, HR 3235 Advocacy w. CMS related to state Medicaid 1115 waiver approvals Multi-Cancer Early Detection Screening Coverage Act of 2020, HR 8845

FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding of the World Health Organization and for cervical cancer screening & treatment and HPV vaccination; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE). HR 133, Consolidated Appropriations Act, 2021 HR 8337, Making continuing appropriations for fiscal year 2021, and for other purposes HR 925, the HEROES Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act H.R.7610, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021 S 178, Legislative vehicle for the Protect Act

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R, 7286 and S 4524, the Quit Because of COVID-19 Act:

FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding of the World Health Organization and for cervical cancer screening & treatment and HPV vaccination; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE). HR 133, Consolidated Appropriations Act, 2021 HR 8337, Making continuing appropriations for fiscal year 2021, and for other purposes HR 925, the HEROES Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act H.R.7610, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021 S 178, Legislative vehicle for the Protect Act

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act HR 1948, Lymphedema Treatment Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Senate introduction (no bill number just yet); Issues related to Medicaid Non-Emergency Medical Transportation; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement. HR 2477, Beneficiary Enrollment Notification and Eligibility Simplification Act (BENES) Regulatory issues related to Medicaid and value-based payment HR 7663, Protecting Access to Post COVID 19 Telehealth Act of 2020 The Access to Genetic Counselor Services Act of 2019, HR 3235 Advocacy w. CMS related to state Medicaid 1115 waiver approvals Multi-Cancer Early Detection Screening Coverage Act of 2020, HR 8845

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending), S. 178 (legislative vehicle for the Protect Act), and HR 925, The Heroes Act. Medical expense deduction - lowering the percentage to 7.5%

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R, 7286 and S 4524, the Quit Because of COVID-19 Act:

FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding of the World Health Organization and for cervical cancer screening & treatment and HPV vaccination; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE). HR 8337, Making continuing appropriations for fiscal year 2021, and for other purposes HR 925, the HEROES Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act H.R.7610, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021 S 178, Legislative vehicle for the Protect Act

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R, 7286 and S 4524, the Quit Because of COVID-19 Act:

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending), S. 178 (legislative vehicle for the Protect Act), and HR 925, The Heroes Act. Regulations on health care sharing ministries and direct primary care arrangements

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act HR 1948, Lymphedema Treatment Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Senate introduction (no bill number just yet); Issues related to Medicaid Non-Emergency Medical Transportation; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement. HR 2477, Beneficiary Enrollment Notification and Eligibility Simplification Act (BENES) Regulatory issues related to Medicaid and value-based payment HR 7663, Protecting Access to Post COVID 19 Telehealth Act of 2020

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act HR 3436, Chronic Care Management Improvement Act HR 1948, Lymphedema Treatment Act; HR 6808, Patient Navigation Assistance Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Issues related to Medicaid Non-Emergency Medical Transportation; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement.

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending)

FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding for cervical cancer screening & treatment and HPV vaccination; and issues related to highway authorization and appropriations. HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6201, Families First Coronavirus Response Act (Medicaid and Medicare provisions) HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Medicaid and Medicare provisions) H.R. 748 Coronavirus Aid, Relief, and Economic Security Act HR 1948, Lymphedema Treatment Act; HR 6808, Patient Navigation Assistance Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; CMS-issued regulations pertaining to Medicare Part B reimbursement - the CY2020 Medicare Physician Fee Schedule; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; The Healthy Adult Opportunity guidance from CMS on allowing states to block grant their Medicaid programs Issues related to Medicaid Non-Emergency Medical Transportation; and S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6201, Families First Coronavirus Response Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; and S. 1608, the Promoting Physical Activity for Americans Act.

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations.

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, issues regarding the medical expense deduction, and issues regarding economic relief for nonprofit organizations. HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to the medical expense deduction and unrelated business income taxation (UBIT) in H.R. 1865, Further Consolidated Appropriations Act, 2020. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act.

FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding for cervical cancer screening & treatment and HPV vaccination; and issues related to highway authorization and appropriations.

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to the medical expense deduction and unrelated business income taxation (UBIT) in H.R. 1865, Further Consolidated Appropriations Act, 2020.

Issues relating to requirements for ride hailing vehicles and companies, S. 1871, Samis Law. Issues relating to highway/transportation reauthorization and appropriations.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1948, Lymphedema Treatment Act; HR 6808, Patient Navigation Assistance Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; S.2218 and H.R 4821, the Covering Our FAS Allies (COFA) Act & issues related to Medicaid coverage for Compacts of Free Association (COFA) migrants; CMS-issued regulations pertaining to Medicare Part B reimbursement - the CY2020 Medicare Physician Fee Schedule; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program; Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act; H.R. 3, the Lower Drug Prices Now Act - legislation for lowering prescription drug costs, lowering out of pocket expenses for Medicare beneficiaries, and placing a cap on Medicare Part D; S. 2543, the Prescription Drug Pricing Reduction Act of 2019 - legislation for lowering prescription drug costs, lowering out of pocket costs for Medicare beneficiaries, and placing a cap on Medicare Part D; Issues related to Medicaid Non-Emergency Medical Transportation; and S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 HR___, Medical Records Fairness Act (Rep. Bill Foster, D-IL); S. 2497, the Dependent Income Exclusion Act; SJ Res 52, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; Issues related to prescription drug costs - H.R. 3, the Lower Prescription Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act of 2019; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; S. 2546 & H.R. 2279, the Safe Step Act of 2019 - amends the Employee Retirement Income Security Act (ERISA) to require group health plans to provide an exception process for any medication step therapy protocol, tools used by health plans to control spending on patients medications, to help ensure patients are able to safely and efficiently access treatment; S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; S. 1608, the Promoting Physical Activity for Americans Act; and Issues related to the nomination of Dr. Stephen Hahn to be Commissioner of the Food and Drug Administration.

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 3835, the Cancer Care Planning and Communications Act; CMS-issued regulations pertaining to Medicare Part B reimbursement - the CY2020 Medicare Physician Fee Schedule; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program; Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act; H.R. 3, the Lower Drug Prices Now Act - legislation for lowering prescription drug costs, lowering out of pocket expenses for Medicare beneficiaries, and placing a cap on Medicare Part D; S. 2543, the Prescription Drug Pricing Reduction Act of 2019 - legislation for lowering prescription drug costs, lowering out of pocket costs for Medicare beneficiaries, and placing a cap on Medicare Part D; and Issues related to Medicaid Non-Emergency Medical Transportation.

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; S. 655 and H.R.1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act; S. 1048 and H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act; H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019; H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019; S. 1258 and H.R. 2411, Tobacco to 21 Act; Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation; H.R. 293, Youth Vaping Prevention Act of 2019; S. 616, E-Cigarette youth Protection Act; S. 1253, Preventing Online Sales of E-Cigarettes to Children Act; S. 1541, Tobacco-Free Youth Act; S. 1895, Lower Health Care Costs Act regarding tobacco 21 age of sale provisions; S 1832, Smoke-Free Schools Act; S. 2726, Banning Smoking on Amtrak Act of 2019; and Issues related to smoke-free policies for the Veterans Health Administration, H.R. 3700 and S. 2106. Issues related to electronic cigarettes: H.R. 4249, Stop Vaping Ads Act; S. 2550, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019; and S. 2519, Ending New Nicotine Dependencies Act of 2019 (ENND Act). Issues related to taxation of tobacco products: and S. 2463, E-cigarette Tax Parity Act; S. 2517, Tobacco Tax Equity Act of 2019.

FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; funding for development of nuclear isotopes for medical diagnostic technology; issues related to global health funding for cervical cancer screening & treatment and HPV vaccination; and and issues related to highway authorization and appropriations.

Issues relating to requirements for ride hailing vehicles and companies, S. 1871, Samis Law. Issues relating to highway/transportation reauthorization and appropriations.

FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for development of nuclear isotopes for medical diagnostic technology; and issues related to global health funding for cervical cancer screening & treatment and HPV vaccination.

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 1010, to provide that the short-term rule has no force or effect; HR 986 & S 466, Protecting Americans with Pre-Existing Conditions Act; HR 1425, State Health Care Premium Reduction Act; HR 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019; HR 1884, Protecting Pre-Existing Conditions & Making Health Care More Affordable Act of 2019; HR 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019; HR 1868, the Health Care Affordability Act, to expand subsidies in the ACA individual marketplace HR 1870, the Family Health Care Affordability Act, to fix the family glitch S 1935, the Family Coverage Act, to fix the family glitch Issues related to surprise billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Issues related to Breast Density and Mammography Reporting; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 1948 & S. 518, the Lymphedema Treatment Act H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; and Cannabis research issues, including S. 2032.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 3107, Improving Seniors Timely Access to Care Act of 2019, on prior authorization in the Medicare Advantage Program CMS-issued regulations pertaining to Medicare Part B reimbursement; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program; Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act. Issues related to utilization management in Medicare Part D plans; issues related to the Medicare Part D caps Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; States Achieve Medicaid Expansion (SAME) Act, S. 585, to ensure states receive the same matching funds regardless of when they expand their Medicaid program; Lymphedema Treatment Act, HR 1948, on Medicare reimbursement for supplies needed by lymphedema patients; CMS-issued regulations pertaining to Medicare Part B reimbursement; Draft legislation on establishment of Medicaid reimbursement for patient navigation; Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to Medicare coverage for BCRA testing and preventive surgery; Issues related to utilization management in Medicare Part D plans; Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.

FY 2019 and FY 2020 federal appropriations for: The Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment; and, issues regarding future work and funding of the CDC tobacco work. FY 2020 federal appropriations for: cancer research and prevention funding at the NIH, NCI and CDC.

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019; H.R. 2111 and S. 1048, The Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act, and issues regarding age of sale of tobacco products; Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation; Issues related to tobacco taxes, flavored tobacco products, and online sale of tobacco products, H.R. 293, Youth Vaping Prevention Act of 2019; and Issues related to smoke-free policies for the Veterans Health Administration.

Issues regarding expanding the availability of the charitable deduction for non-itemizers and issues respecting charitable giving and life income planning and issues respecting the medical expense deduction.

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control as considered in House and Senate, FY18 and The FY19 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273. Issues regarding flavors in tobacco products including e-cigarettes and cigars respecting S.3319, the SAFE Kids Act, and development of similar legislation. Issues relating to trade and investment agreements and tobacco. Issues regarding CDC future funding and work related to tobacco.

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479 and regulatory issues related to the Medicare coinsurance issue in these bills; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on establishment of Medicaid payment for patient navigation. Issues relating to Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial. Issues related to Medicare coverage for BCRA testing and preventive surgery (proposed Murkowski legislation).

Expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988, S. 2123 and H.R. 5771, The Charitable Giving Tax Deduction Act. H.R. 1337, Legacy IRA Act respecting charitable giving and life income planning, and H.R. 6760, the Protecting Family and Small Business Tax Cuts Act of 2018 respecting the medical expense deduction

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on establishment of Medicaid payment for patient navigation.

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; H.R. 4122 & S. 2006, the Breast Density & Mammography Reporting Act; H.R.820 & S.292, the Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, issues related to reform of laboratory and diagnostic tests and the development of a new discussion draft for the Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. The proposed Medical Records Fairness Act (no number yet). Issues regarding the Affordable Care Act premium tax credits and catastrophic plans, HR 6311. Issues regarding protections for people with pre-existing conditions, including S. 3388, HR 6898, and H. Res. 1066. Resolutions to disapprove the short-term rule, H.J. Res 140 and S. J. Res. 63. Advocacy against including the Association Health Plan provision of the House Farm bill in the conference report, H.R. 2 and s. 3042 (section 6004 of the House-passed version of the legislation). Issues involving patient navigation, including the Patient Navigation Assistance Act, HR 6808. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on patient access to medical records. Draft legislation on FDA regulation of laboratory tests. H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018. Issues related to caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act.

Federal budget and appropriations for cancer research and programs, including: H.R. 6157, the Defense and Labor, HHS, Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 respecting FY 2019 federal appropriations for NIH, NCI, and CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act, and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act;; and issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment.

Expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and, S. 2123. and H.R. 5771, The Charitable Giving Tax Deduction Act. H.R. 1337, Legacy IRA Act respecting charitable giving and life income planning.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 and FY19 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.HR 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on establishment of Medicaid payment for patient navigation.

Federal budget and appropriations for cancer research and programs, including: HR 1625, The Consolidated Approp. Act of 2018 respecting FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Creating parity in taxation of tobacco products respecting S. 1837; HR1 tax bill relating to its implementation roll out and impact on charitable deductions.

HR1 tax bill, issues relating to the tax treatment of nonprofits, including charitable deductions, elimination of the individual fee for the Affordable Care Act, deduction of health care costs by individual tax payers, and availability of the Orphan Drug Tax Credit. Also expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and S. 2123. Also, creating parity in taxation of tobacco products respecting S. 1837

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations, and H.R. 2194 Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations, and H.R. 2194 Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.

HR1 tax bill, issues relating to the tax treatment of nonprofits, including charitable deductions, elimination of the individual fee for the Affordable Care Act, deduction of health care costs by individual tax payers, and availability of the Orphan Drug Tax Credit. Also expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and S. 2123. Also, creating parity in taxation of tobacco products respecting S. 1837

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations, and H.R. 2194 Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.

HR1 tax bill, issues relating to the tax treatment of nonprofits, including charitable deductions, elimination of the individual fee for the Affordable Care Act, deduction of health care costs by individual tax payers, and availability of the Orphan Drug Tax Credit. Also expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and S. 2123. Also, creating parity in taxation of tobacco products respecting S. 1837

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act. Also, issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Federal budget and appropriations for cancer research and programs, including: FY 2017 and FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act. Also, issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act.

Federal budget and appropriations for cancer research and programs, including: FY 2017 and FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act. Also, issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act.

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; and, H.R.820 & S.292, Childhood Cancer STAR Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430, Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Federal budget and appropriations for cancer research and programs, including: federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including certain votes on issues relating to NIH and cancer moonshot funding in the context of H.R. 2028, the Continuing and Security Assistance Appropriations Act; and, H.R. 34, the 21st Century Cures Act. Also issues relating to non-communicable diseases with respect to S.3117, the State/Foreign Operations FY17 Appropriations legislation, the House companion draft Appropriations bill, and the Continuing Resolution for FY17 enacted prior to October 1, 2016.

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act; and H.R.1190, Protecting Seniors' Access to Medicare Act and issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430, Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Federal budget and appropriations for cancer research and programs, including: federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including certain votes on issues relating to NIH and cancer moonshot funding in the context of H.R. 2028, the Continuing and Security Assistance Appropriations Act; and, H.R. 34, the 21st Century Cures Act. Also issues relating to non-communicable diseases with respect to S.3117, the State/Foreign Operations FY17 Appropriations legislation, the House companion draft Appropriations bill, and the Continuing Resolution for FY17 enacted prior to October 1, 2016.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act; and H.R.1190, Protecting Seniors' Access to Medicare Act and issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430, Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430, Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opiod prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments.

Federal budget and appropriations for cancer research and programs, including: federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; and programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, global health, and other appropriated accounts relating to cancer, including H. Con. Res. 25, the FY17 budget resolution, H.R.__, the FY17 Agriculture Appropriations legislation and issues relating to NIH funding in the context of the Senate HELP Committee Medical Innovation legislation.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; and regulations relating to tanning beds. In addition, regulatory issues before the F.D.A relating to laboratory developed tests, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, H.R.644 - America Gives More Act; and CDC opioid prescription guidelines.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; and regulations relating to tanning beds. In addition, regulatory issues before the F.D.A relating to laboratory developed tests, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, H.R.644 - America Gives More Act; and CDC opioid prescription guidelines.

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act; and H.R.1190, Protecting Seniors' Access to Medicare Act.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, global health, and other appropriated accounts relating to cancer, including H.R.6, the 21st Century Cures Act; H.R.3020/S.1695, Departments of Labor HHS Appropriations legislation for FY16; H.R.2772, S.1725, Department of State, Foreign Operations Appropriations for FY16; S.1558, Department of Defense Appropriations Act; and H.R.2029, Mil-Con Veterans Affairs (Omnibus) Appropriations Act.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues before CMS relating to: Medicare payment for preventive screening; coordinated patient care; care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act of 2015; and H.R.1190, Protecting Seniors' Access to Medicare Act.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, product regulation, and smokefree environments, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to tobacco and trade, including: the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership; proposed FDA regulation of electronic cigarettes and/or cigars; H.R.478/S.430,Protecting Children from Electronic Cigarette Advertising Act; H.R.3042, Stop Tobacco Sales to Youth Act; S.450, Tobacco Tax Equity Act; H.R.1749, STOP Act; and S.1129, Tobacco Tax and Enforcement Reform Act. Issues related to tobacco control related appropriated accounts, including CDC's Office of Smoking & Health in H.R.2029, Omnibus Appropriations legislation.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues before CMS relating to: Medicare payment for preventive screening; coordinated patient care; care planning; H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act of 2015; and H.R.1190, Protecting Seniors' Access to Medicare Act.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, global health, and other appropriated accounts relating to cancer, including H.R.6, the 21st Century Cures Act; H.R.3020/S.1695, Departments of Labor HHS Appropriations legislation for FY16; H.R.2772, S.1725, Department of State, Foreign Operations Appropriations for FY16; and S.1558, Department of Defense Appropriations Act.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including H.R.3119, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act, and regulations relating to tanning beds. In addition, regulatory issues before the F.D.A relating to laboratory developed tests, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act; an issues before the CDC, including opioid prescription guidelines.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including follow-on legislation to H.R.1666 & S.2800, the Patient Centered Quality Care for Life Act, and, H.R.1339 (IH) & S.641, the Palliative Care and Hospice Education and Training Act (113th Congress), H.R.716 & S.370, the Breast Density & Mammography Reporting Act, and regulations relating to tanning beds. In addition, regulatory issues before the F.D.A relating to laboratory developed tests, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, global health, and other appropriated accounts relating to cancer, including H.Con.Res.27 & S.Con.Res.11, FY16 proposed budget resolutions; H.R.6, the 21st Century Cures Act; H.R.3020/S.1695, Departments of Labor HHS Appropriations legislation for FY16; H.R.2772, S.1725, Department of State, Foreign Operations Appropriations for FY16; and S.1558S, Department of Defense Appropriations Act.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations: (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC) and tobacco tax proposals contained in the President's FY16 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership, legislation relating to trade promotion authority, and proposed FDA regulation of electronic cigarettes and/or cigars.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS quality based payment programs and H.R.1220 & S.624, Removing Barriers to Colorectal Cancer Screening Act of 2015; H.R.2810 & H.R.2, the Medicare Access and CHIP Reauthorization Act of 2015 and issues within related to Federally Qualified Health Centers.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations: (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC). S.39, Healthy Lifestyles and Prevention America Act, H.R.792 & S.772, cigar exemption from FDA regulations; S.194, Tobacco Tax Equity Act and tobacco tax proposals contained in the President's FY15 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership, legislation relating to trade promotion authority, and proposed cigar exemption amendment to Agriculture Appropriations legislation for FY15, H.R.4800 & S.2389, and proposed FDA regulation of electronic cigarettes.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, global health, and other appropriated accounts relating to cancer. Also, un-numbered House & Senate Labor-HHS Appropriations drafts for FY15, H.J.Res. 124, Continuing Appropriations Resolution, 2015, and H.R.83, FY 2015 Omnibus, Consolidated and Further Continuing Appropriations Act.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", and H.R.1070 & S.2348, Removing Barriers to Colorectal Cancer Screening Act of 2013; H.R.2810, Medicare Patient Access & Quality Improvement Act, S.1871, the SGR Repeal & Medicare BeneficiaryAccess Act, and S. 2157, the Commonsense Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations: (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC). S.39, Healthy Lifestyles and PreventionAmerica Act, H.R.792 & S.772, cigar exemption from FDA regulations; S.194, Tobacco Tax Equity Act and tobacco tax proposals contained in the President's FY15 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership, legislation relating to trade promotion authority, and proposed cigar exemption amendment to Agriculture Appropriations legislation for FY15, H.R.4800 & S.2389.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, and international health. President Obama's FY15 budget, S.1284, the FY14 Labor, Health & Human Resources Appropriations Act; H.J.Res.59, Continuing Resolution; H.R.2775,Continuing Appropriations; and H.R.3547, Omnibus Appropriations for FY14, and matters relating to the impact of the government-wide sequester as it affects CDC, NIH, NCI, Prevention & Public Health Fund, and other appropriated accounts relating to cancer.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including the following legislation to be reintroduced from the 112th Congress: H.R.1851 and S.881, the Family Act; the as-yet not introduced Health Equity and Accountability Act; H.R.1666, the Patient Centered Quality Care For Life Act, and, H.R.1339 & S.641, the Palliative Care andHospice Education and Training Act; S.621 and H.R.2607 and S.1251, the Caroline Pryce Walker Conquer Childhood Cancer Act; H.R.2058 & S.1247 the Childhood Cancer Survivors Quality of Life Act; H.R.2019, the Kids First Research Act; and H.R.460, the Patients' Access to Treatments Act; H.R.3404, the Breast Density & Mammography Reporting Act, H.R.4250 and S.2141, legislation to create a new FDA approval pathway for O.T.C. sunscreen products.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, and global health. President Obama's FY15 budget, S.1284, the FY14 Labor, Health & Human Resources Appropriations Act; and H.R.3547, Omnibus Appropriations for FY14, andmatters relating to the impact of the government-wide sequester as it affects CDC, NIH, NCI, Prevention & Public Health Fund, and other appropriated accounts relating to cancer. Also, H.Con.Res. 96, House-passed budget for FY15, and un-numbered House & Senate Labor-HHS Appropriations drafts for FY15.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070 & S.2348, Removing Barriers to Colorectal Cancer Screening Act of 2013; H.R.2810, Medicare Patient Access & QualityImprovement Act, S.1871, the SGR Repeal & Medicare Beneficiary Access Act, and S. 2157, the Commonsense Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070, Removing Barriers to Colorectal Cancer Screening Act of 2013; H.R.2810, Medicare Patient Access & QualityImprovement Act, S.1871, the SGR Repeal & Medicare Beneficiary Access Act, and S. 2157, the Commonsense Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC). S.39, Healthy Lifestyles and Prevention America Act, H.R.792 & S.772, cigar exemptionfrom FDA regulations; S.194, Tobacco Tax Equity Act and tobacco tax proposals contained in the President's FY15 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership, and legislation relating to trade promotion authority.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070, Removing Barriers to Colorectal Cancer Screening Act of 2013; H.R.2810, Medicare Patient Access & QualityImprovement Act and S.1871, the SGR Repeal & Medicare Beneficiary Access Act.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including the following legislation to be reintroduced from the 112th Congress: H.R.1851 and S.881, the Family Act; the as-yet not introduced Health Equity and Accountability Act; H.R.1666, the Patient Centered Quality Care For Life Act, and, H.R.1339 & S.641, the Palliative Care andHospice Education and Training Act; S.621 and H.R.2607 and S.1251, the Caroline Pryce Walker Conquer Childhood Cancer Act; H.R.2058 & S.1247 the Childhood Cancer Survivors Quality of Life Act; H.R.2019, the Kids First Research Act; and H.R.460, the Patients' Access to Treatments Act; H.R.3404, the Breast Density & Mammography Reporting Act.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid. Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070, Removing Barriers to Colorectal Cancer Screening Act of 2013.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC). S.39, Healthy Lifestyles and Prevention America Act, H.R.792 & S.772, cigar exemptionfrom FDA regulations; S.194, Tobacco Tax Equity Act and tobacco tax proposals contained in the President's FY14 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership.

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation to be reintroduced from the 112th Congress; the Sun Act, the Family Act, Health Equity and Accountability Act, and the Patient Centered Quality of Care Act. Also, H.R.1339 & S. 641, the Palliative Care and Hospice Education and Training Act; S. 621 and H.R. 1285, the Safe Prescribing Act;H.R. 1366, the Stop Oxy Abuse Act; and issues relating to tanning beds before the FDA, HHS and the House and Senate.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070, Removing Barriers to Colorectal Cancer Screening Act of 2013.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, and international health. S.Con.Res. 8 FY14 Senate Budget Resolution, H.R. 993 Consolidated & Further Continuing Appropriations Act of 2013. H.J.Res.117, the Continuing AppropriationsResolution Act; and the President's FY14 Budget.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC). S. 39, Healthy Lifestyles and Prevention America Act,H.R. 792 & S. 772, cigar exemption from FDA regulations; S. 194, Tobacco Tax Equity Act and tobacco tax proposals contained in the President's FY14 Budget. Issues relating to tobacco and trade, including the Trans-Pacific Partnership and Transatlantic Trade and Investment Partnership.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, and international health. S.Con.Res. 8 FY14 Senate Budget Resolution, H.J.Res.117, the Continuing Appropriations Resolution Act; the President's FY14 Budget; and S.1284, the FY14 Labor,Health & Human Resources Appropriations Act.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", general deficit reduction issues impacting Medicare & Medicaid, and H.R.1070, Removing Barriers to Colorectal Cancer Screening Act of 2013.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, patient quality of life, and international health. S.Con.Res. 8 FY14 Senate Budget Resolution, H.R. 993 Consolidated & Further Continuing Appropriations Act of 2013. H.J.Res.117, the Continuing AppropriationsResolution Act; and the President's FY14 Budget.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", S.2068, S.2288, H.R.1206, the Access to Independent Health Insurance Advisors Act of 2012, general deficit reduction issues impacting Medicare &Medicaid.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", S.2068, S.2288, H.R.1206, the Access to Independent Health Insurance Advisors Act of 2012, general deficit reduction issues impacting Medicare & Medicaid.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) Framework Convention on Tobacco Control (FCTC); and (4) issues relating to NIH reorganization. Legislation includes H.R.3186 and S.1706, Smuggled Tobacco Prevention Act; H.R.3382, Smoke-Free Federal Building Act; S.1403, IDEA Full Funding Act; and H.R.65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R.5973. Issues relating to tobacco and trade, including the Trans-Pacific Partnership.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. H.J.Res.117, the Continuing Appropriations Resolution Act; S.3295, the Labor, HHS, Education Appropriations Act, and similar legislation pending in the House of Representatives.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing", S.2068, S.2288, H.R.1206, the Access to Independent Health Insurance Advisors Act of 2012, general deficit reduction issues impacting Medicare & Medicaid.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC (S.3295); the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; and issues relating to consolidation of categorized cancer prevention programs of the Centers for Disease Control and Prevention.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S.868 and H.R.1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service within CMS "value-based purchasing".

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R.10, the Regulations from the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization. Legislation includes H.R.3186 and S.1706, Smuggled Tobacco Prevention Act; H.R.3382, Smoke-Free Federal Building Act; S.1403, IDEA Full Funding Act; and H.R.65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R.5973.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of Scrutiny A Act of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011.

Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health; and matters under consideration by the Joint Select Committee on Deficit Reduction. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; S. 1599, legislation including draft House text of legislation making appropriations for L-HHS FY 12; H.R. 2055 and S. 3671, Consolidated Appropriations Act of 2012.

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of Scrutiny A Act of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011.

Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S. 717 and H.R. 6224; H. Con. Res. 34, establishing a budget for the US Government for FY 12; S. 868 and H.R. 1683, the State Flexibility Act (MOE); and matters under consideration by the Joint Select Committee on Deficit Reduction.

Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S 494 and HR 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; HR 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; HR 1217, Repeal Prevention and Public Health Fund; HR 1740 and HR 5560, the Quality Cancer Care for Life Act of 2010; HR 2941 and S 3493; HR 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S. 1064, the Sun Act; S 965, the Family Act; HR2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act.

Issues related to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L.111-31); (2) cessation and prevention programs authorized as part of P.L.111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R.10, the Regulations from the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization.

Issues related to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L.111-31), and cessation and prevention programs authorized as part of P.L.111-148, the Patient Protection & Affordable Care Act of 2010, legislation regarding Congressional review/approval of regulations, including H.R.10, the Regulations from the Executive in Need of Scrutiny Act of 2011 , and Framework Convention on Tobacco Control (FCTC), and issues relating to NIH reorganization.

Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, tobacco regulation & cessation programs, patient navigator programs, and international health programs, including S.3686, the Senate Labor-HHS appropriations for FY11, and Senate Amendment to H.3081, H.J. Res.101, H.J. Res.105 and H.3082, the 1st, 2nd, 3rd, and 4th Continuing Appropriations Act, 2011.

Issues related to implementation of changes to Medicare and Medicaid, pursuant to P.L.111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S.717 and H.R.6224, the 21st Century Cancer ALERT Act.

Issues related to health care reform, Medicare and Medicaid, coverage of cancer-related services and prevention measures, including H.R.2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to implentation of Medicare & Medicaid related provisions enacted as part of P.L.111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S.717 and H.R.6224, the 21st Century Cancer ALERT Act.

Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, tobacco regulation & cessation programs, patient navigator programs, and international health programs, including S.3686, the Senate Labor-HHS appropriations for FY11, and the comparable unnamed House bill.